CHC cirrhotic patients’ demographic and baseline clinical characteristics overall and by adherent (every 6 months) versus non-adherent status
| Characteristics | Overall (n=2366) | Adherent (n=577) | Non-adherent (n=1789) | P values |
| Age | 54±10 | 56±9 | 54±10 | <0.00001 |
| Male % | 62.3 | 62.1 | 62.4 | 0.89 |
| Ethnicity % | ||||
| Caucasian | 48.3 | 48.7 | 48.2 | <0.0001 |
| Latino/Hispanic | 21.9 | 25.0 | 21.0 | |
| Asian | 10.7 | 17.3 | 8.6 | |
| African-American | 5.6 | 4.7 | 5.9 | |
| Other/Unknown | 13.4 | 4.3 | 16.4 | |
| Cirrhosis % | ||||
| Compensated | 54.4 | 45.8 | 57.2 | <0.0001 |
| Decompensated | 45.6 | 54.3 | 42.8 | |
| Alcohol consumption % | ||||
| Drinker | 33.6 | 24.5 | 36.2 | 0.001 |
| Smoking status % | ||||
| Never smoker | 41.5 | 44.9 | 39.8 | <0.0001 |
| Former smoker | 39.5 | 43.3 | 37.6 | |
| Current smoker | 18.9 | 11.8 | 22.6 | |
| MELD score ≥10 | 64.9 | 71.3 | 62.1 | <0.0001 |
| CPT class % | ||||
| A | 42.0 | 35.4 | 44.7 | 0.045 |
| B | 37.9 | 41.9 | 36.2 | |
| C | 20.2 | 22.8 | 19.1 | |
| Platelets (×103/mcL) | 146±89 | 128±77 | 153±92 | <0.00001 |
| INR (units) | 1.4±0.6 | 1.5±0.7 | 1.4±0.5 | 0.06 |
| Total bilirubin (mg/dL) | 1.2 (1–2.2) | 1.4 (1–2.7) | 1.1 (1–2.1) | <0.00001 |
| Albumin (g/dL) | 3.4±0.7 | 3.5±0.6 | 3.4±0.7 | 0.24 |
| AST (units/L) | 78 (50–97) | 86 (63–98) | 73 (46–96) | <0.00001 |
| ALT (units/L) | 75 (49-96) | 83 (59-97) | 72 (45-96) | <0.00001 |
| Median clinical visits per year | 2.7 (0.9–8) | 3.4 (0.9–10) | 2.5 (0.8–7) | 0.003 |
| Median follow-up (months) | 35.6 (22–62) | 25.5 (16–49) | 39.5 (24–65) | <0.0001 |
| HCC diagnosis during follow-up | 9.6% (n=228) | 26.2% (n=151) | 4.3% (n=77) | <0.0001 |
| Death % | 27.8 | 27.4 | 28.0 | 0.79 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHC, chronic hepatitis C; CPT, Child-Pugh-Turcotte; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease.